Unknown Digestion, Kidneys & Other Organs NIHR-supported project Lungs & Breathing
A Multicenter, Long-term, Randomized, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants with Sjögren’s Syndrome (SS)
About this grant
This summary is based on the grant title only — the full abstract was not available.
No substantive source abstract was published for this research project funded by NIHR.
Researchers
Tamir Malley (Principal Investigator)
Related Research
Grants with similar aims, by meaning.
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren’s Syndrome With Moderate-to-Severe Symptom State
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Subjects with Sjögren’s Syndrome (SS)
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity.
HZNP-DAZ-301 - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity
HZNP-DAZ-301 A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjogren's Syndrome With Moderate-to-severe Systemic Disease Activity
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know